Pathway-specific gene delivery is requisite for understanding complex neuronal systems in which neurons that project to different target regions are locally intermingled. However, conventional genetic tools cannot achieve simultaneous, independent gene delivery into multiple target cells with high efficiency and low cross-reactivity. In this study, we systematically screened all receptor-envelope pairs resulting from the combination of four avian sarcoma leukosis virus (ASLV) envelopes (EnvA, EnvB, EnvC, and EnvE) and five engineered avianderived receptors (TVA950, TVB   S3 , TVC, TVB T , and DR-46TVB) in vitro. Four of the 20 pairs exhibited both high infection rates (TVA-EnvA, 99.6%; TVB S3 -EnvB, 97.7%; TVC-EnvC, 98.2%; and DR-46TVB-EnvE, 98.8%) and low cross-reactivity (<2.5%). Next, we tested these four receptor-envelope pairs in vivo in a pathway-specific gene-transfer method. Neurons projecting into a limited somatosensory area were labeled with each receptor by retrograde gene transfer. Three of the four pairs exhibited selective transduction into thalamocortical neurons expressing the paired receptor (>98%), with no observed crossreaction. Finally, by expressing three receptor types in a single animal, we achieved pathway-specific, differential fluorescent labeling of three thalamic neuronal populations, each projecting into different somatosensory areas. Thus, we identified three orthogonal pairs from the list of ASLV subgroups and established a new vector system that provides a simultaneous, independent, and highly specific genetic tool for transferring genes into multiple target cells in vivo. Our approach is broadly applicable to pathway-specific labeling and functional analysis of diverse neuronal systems. avian sarcoma leukosis virus | pseudotyped lentiviral vector | pathway-specific gene transfer
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Despite their usefulness, these technologies can simultaneously manipulate no more than two neural pathways-a number that is far from sufficient for a dissection of natural brain circuitry. Therefore, it is necessary to increase the number of available tools. One challenge to doing so is that all such tools need to be orthogonal; in other words, the biological reactions on which they are based must not cross-react.
A number of biochemical mechanisms are potentially applicable to orthogonal gene expression systems. One of the most promising candidates is the use of specific combinations of virus envelope (Env) proteins and corresponding receptors. Because viral vectors pseudotyped with Env proteins exclusively infect cells that express compatible receptors, exogenous expression of receptors in target cells provides a specific guide for viral entry. However, some viruses can use more than one molecular species as receptors, and these receptors provide a variety of functions essential for viral entry. In simple situations, receptors bind to virus envelopes and initiate endocytic uptake of viruses; alternatively, receptors affect cellular signaling pathways that facilitate virus entry, or they directly activate fusion/penetration processes by inducing conformational changes in Env proteins (10) .
Among the enveloped viruses, we focused on avian sarcoma leukosis virus subgroups (ASLVs) for three reasons. First, ASLV's natural host range is restricted to birds. Therefore, it is likely that ASLV-pseudotyped viral vectors will exhibit low, nonspecific infectivity toward mammalian neurons via endogenous receptors. Second, ASLVs are reported to require single molecular species as receptors, and this simple mode of infection is suitable for adaptation as a conditional gene-delivery system. Third, many different Env and receptor proteins are available from among six distinct ASLV subgroups (A, B, C, D, E, and J) and 10 different receptors (11) , and there is evidence that some ASLV Env proteins exhibit specific binding to disparate receptor sequences. For example, chicken TVA protein belongs to the family of lowdensity lipoprotein receptors and determines susceptibility to ASLV-A (12) . The tumor necrosis factor receptor-related proteins TVB S1 and TVB S3 confer susceptibility to ASLV-B/-D/-E,
Significance
Genetic dissection of multiple neural pathways remains challenging because of the limited number of genetic methods that can be used simultaneously. To overcome this limitation, we used modified avian sarcoma and leukosis virus envelopes and receptors to develop highly orthogonal genetic tools that can achieve expression of different genes in different target cells. From in vitro and in vivo screens, we identified tools that can specifically transfer genes of interest into mammalian neurons via engineered receptors, with minimal unintended interactions. Using this approach, we achieved pathway-specific, differential fluorescent labeling of three thalamic neuronal populations, each projecting into different cortical regions. Thus, our approach provides independent, simultaneous, and specific genetic tools for manipulating intermingled neural pathways in vivo.
and ASLV-B/-D, respectively (13) . ASLV-C uses the TVC protein of the butyrophilin family, which contains two Ig-like domains (14) . TVB T , a turkey homolog of TVB, is an ASLV-E-specific receptor (15) . Finally, ASLV-J uses the chicken multimembrane-spanning cell-surface protein Na + /H + exchanger type 1 (chNHE1) as a receptor (16) .
However, no study to date has systematically and quantitatively determined which types of ASLVs can infect with high efficiency mammalian cells expressing a single receptor, and no study has shown which combination of envelopes and receptors of ASLV specifically interact with each other. In this study, we first performed in vitro and in vivo screens to identify orthogonal receptor-envelope pairs. We then conducted a proof-of-concept study in vivo to demonstrate that these orthogonal pairs can achieve pathway-specific differential fluorescent labeling of multiple neuronal populations, each projecting to different cortical regions. Our findings expand the repertoire of genetic tools that can be used to dissect and manipulate the complex neural networks created by intermingled neurons projecting to different target regions.
Results
Putative Orthogonal ASLV Receptor-Envelope Pairs. The various ASLV subgroups exhibit different infectious properties in chicken cell lines (CEFs and DF-1 cells) (12) (13) (14) (15) (16) (17) . Based on these data, we estimated the feasibility of six envelopes and seven receptors as genetic tools, and eliminated several (TVB
S1
, ASLV-D envelope, ASLV-J envelope, and chNHE1) for the following reasons: TVB S1 is a nonspecific cellular receptor for ASLV-B, -D, and -E (13, 17); ASLV-D can infect a variety of mammalian cell lines in the absence of exogenous receptors (18) (19) (20) ; and chNHE1, the receptor for ASLV-J (16), may alter neuronal membrane potential. Additionally, we selected TVA950, a transmembrane form, from two splice-variant forms of TVA, even though the other form of TVA [TVA800, a chicken glycophosphatidylinositol (GPI)-anchored form] has been used in previous studies (8, 21, 22) . We chose the transmembrane form because GPI-anchored proteins contain a signal peptide in the C terminus that is cleaved off and replaced by the GPI-anchor, precluding the use of C-terminal epitope tags. This process narrowed down the set of candidates to four receptors (TVA950, TVB S3 , TVC, and TVB T ) and four envelopes (EnvA, EnvB, EnvC, and EnvE) (Fig. 1A) .
Measurement of Orthogonality Between the Receptor-Envelope Pairs in Vitro. To examine the orthogonality of the receptor-envelope pairs, we tested the various combinations to determine which ones afforded specific viral entry and transgene expression in human embryonic kidney (HEK) 293T cells. To mitigate the unwanted side effects associated with the expression of an exogenous transmembrane protein in mammalian cells, we deleted a part of the original intracellular domains from each receptor (Fig. 1B) . In TVA950, the original intracellular domain, except for four amino acid residues, was deleted (12) . In TVB S3 , TVB T , and DR-46TVB, the intracellular domain, except for 107 amino acid residues, was deleted (13, 17) . In TVC, the intracellular domain remained. Epitope tags (HA, c-Myc, V5, and 3× FLAG) were C-terminally fused to the receptors to allow detection by immunohistochemistry. To increase protein half-life according to the mammalian N-end rule (23) , the N termini of the receptors were also modified, such that valine was the second amino acid.
We then developed two types of recombinant lentiviral vectors: FuGB2-pseudotyped bicistronic vectors that coexpressed the engineered receptor and Aequorea coerulescens green fluorescent protein (AcGFP1) and ASLV Env-pseudotyped vectors that expressed mCherry ( Fig. 2A) . The FuGB2-pseudotyped lentiviral vector can transduce neurons by retrograde axonal transport in vivo (24) . Some dividing cells can be also transduced in vitro (25) . In the present study, this vector was used to express ASLV receptors in both in vitro and in vivo experiments. The cytomegalovirus (CMV) promoter was selected because it drives a high level of protein expression in the mammalian brain (26) and has been used previously for TVA expression (8, 21, 27) . We tested all possible receptor-envelope combinations by serially infecting receptor-expressing and Env-pseudotyped vectors into HEK 293T cells. mCherry expression was observed in only five pairs: TVA950-EnvA, TVB S3 -EnvB, TVC-EnvC, TVB T -EnvB, and TVB T -EnvE (Fig. 2 B-E) . Although the results obtained with TVA950-EnvA, TVB
S3
-EnvB, and TVC-EnvC were consistent with those obtained in DF-1 cells, the infection of EnvB vector into TVB T -expressing cells observed in our assays was inconsistent with previous reports.
We next sought to rationally design an alternative EnvE-specific receptor for TVB T . The chimeric protein DR-46TVB was engineered by exchanging the first cysteine-rich domain of Receptor: TVA800, TVA950, TVBS1, TVB S3 ,   TVC, TVB T , and 
chicken TVB

S1
, which is critical for ASLV-B infection (28) , with those of the human TVB homolog DEATH RECEPTOR 5. HEK 293T cells expressing this chimeric receptor expressed mCherry in combination with EnvE vector, but not EnvB vector (Fig. 2F ).
These results were quantitatively confirmed by flow cytometry. A progressive shift to the right was observed only in the histograms for the following six pairs: TVA950-EnvA, TVB S3 -EnvB, TVC-EnvC, TVB T -EnvB, TVB T -EnvE, and DR-46TVB-EnvE (Fig. 3A) . Furthermore, the infection rates (the ratio of AcGFP1/ -EnvB, TVC-EnvC, and DR-46TVB-EnvE were significantly higher than those of the other pairs [one-way analysis of variance (ANOVA) and Scheffé's F-test, P < 0.001] except for TVB T -EnvB and TVB TEnvE ( Fig. 3B and Table S1 ). Together, these data demonstrate that these four pairs (TVA950-EnvA, TVB S3 -EnvB, TVC-EnvC, and DR-46TVB-EnvE) are orthogonal in HEK 293T cells.
Orthogonality of the TVA950-EnvA Pair in Vivo. Having demonstrated that the four aforementioned orthogonal pairs were capable of transferring genes into cultured mammalian cells, we next examined the gene-transfer capability and the orthogonality of our receptors and envelopes in vivo using the thalamocortical system of rats. FuGB2-pseudotyped lentiviral vector shows a high efficiency of gene transfer via retrograde axonal transport. In these in vivo experiments, the receptor genes were transferred into both thalamocortical and cortico-cortical neurons projecting to the injection site (the primary somatosensory cortex) (Fig. S1 ).
By contrast, fluorescent protein genes were expressed only in the thalamocortical neurons by the injection of Env vectors into the thalamus (Fig. S2) . In a pilot study, we injected FuGB2-TVC vector along with a mixture of EnvA/EnvB/EnvC/EnvE vectors into 12 rats. We did not observe any sign of infection by the EnvC vector in these rats in vivo. Hence, the TVC-EnvC pair was not used in the following experiment.
We first tested the specificity of the TVA950-EnvA pair (Fig.  4A ). In these experiments, the retrograde vector expressing TVA950 (FuGB2-TVA950) was injected into the primary somatosensory cortex (S1) ( Orthogonality of the TVB S3 -EnvB Pair in Vivo. We also tested the specificity of the TVB S3 -EnvB pair in vivo (Fig. 5A) . In this experiment, we injected FuGB2-TVB S3 vector into the S1 region and a mixture of EnvA/EnvB/EnvE vectors into the thalamus 3 wk later (Fig. 5B) . The injection coordinates for the FuGB2-TVB S3 vector were 2.5 mm posterior to those used for the FuGB2-TVA950 vector in the rats shown in Fig. 4 . We observed many EGFP-positive axons from thalamic neurons innervating the S1 cortex (Fig. 5C ). The EGFP-positive axons projected into cortical layers I, IV, and VI in the S1 cortex near the FuGB2-TVB S3 vector injection site (Fig. 5D) . To compare the distribution of TVB S3 -positive cells with that of EGFP-positive cells, we performed an immunohistochemical analysis using an anti-cMyc antibody to detect the c-Myc-tagged TVB S3 protein in brain sections; EGFP-positive cells were detected only in the VPM and POm (Fig. 5E) .
We then performed a quantitative immunohistochemical analysis using the c-Myc epitope tag and found that 96.7% of EGFP-positive neurons were also TVB S3 -positive (ratio of EGFP and TVB S3 double-positive neurons to all EGFP-positive neurons: 397/410) (Fig. 5F ). By contrast, neither BFP-nor tdTomato-positive neurons were observed (Fig. 5G) Orthogonality of the DR-46TVB-EnvE Pair in Vivo. We next tested the specificity of the DR-46TVB-EnvE pair in vivo (Fig. 6A) . In these experiments, FuGB2-DR-46TVB vector was injected into the S1 region, and a mixture of EnvA/EnvB/EnvE vectors was injected into the thalamus 3 wk later (Fig. 6B) . The injection coordinates for the FuGB2-DR-46TVB vector in the rats were 2.5 mm posterior to those used for the FuGB2-TVB S3 vector in the rats shown in Fig. 5 . We observed many tdTomato-positive axons from thalamic neurons innervating the S1 cortex (Fig. 6C) . Many tdTomato-positive axons projected into S1 cortical layers I, IV, and VI near the FuGB2-DR-46TVB vector injection site (Fig. 6D) . To compare the distribution of the DR-46TVB-positive cells with that of tdTomato-positive cells in brain sections, we performed an immunohistochemical analysis using an anti-FLAG antibody to detect the 3× FLAG-tagged DR-46TVB protein. The tdTomato-positive cells were detected only in the VPM and POm (Fig. 6E) .
We then performed a quantitative analysis using immunohistochemistry with the 3× FLAG epitope tag and found that 99.9% of tdTomato-positive neurons were also DR-46TVB-positive (ratio of tdTomato and DR-46TVB double-positive neurons to all tdTomato-positive neurons: 502/503) (Fig. 6F) , whereas none were BFP-or EGFP-positive (Fig. 6G) . Among three rats, the average specificity of the DR-46TVB-EnvE pair was 99.7%, the highest among all three receptor-envelope pairs (vs. 99.1% for TVA950-EnvA and 98.7% for TVB S3 -EnvB; Table 1 ). These results confirmed that the EnvE vector leads to the specific transduction of DR-46TVB-positive neurons, and other EnvA/ EnvB vectors do not transduce DR-46TVB-positive or -negative neurons in vivo.
We also examined the orthogonality of the three ASLV receptor-envelope pairs in corticocortical projection neurons in the primary motor cortex (M1) (Fig. S4) . In this experiment, FuGB2 vector encoding the ASLV receptors was first injected to TVA950+  TVA950−  TVA950+  TVA950−  TVA950+  TVA950−  TVA950  A1  5  572  8  0  0  0  0  A2  5  974  8  0  0  0  0  A3  5  1,942  17  0  0  0  0  TVBS3+  TVBS3−  TVBS3+  TVBS3−  TVBS3+  TVBS3−  TVBS3  B1  5  0  0  1,200  12  0  0  B2  5  0  0  384  13  0  0  B3  5  0  0  954  10  0  0  DR-46TVB+  DR-46TVB−  DR-46TVB+  DR-46TVB−  DR-46TVB+  DR-46TVB−  DR-46TVB  D1  5  0  0  0  0  400  2  D2  5 M1, and then a second injection of Env vectors was administered to the contralateral M1. The results showed the orthogonality of the three ASLV receptor-envelope pairs in corticocortical neurons of M1 (Table S2) , as well as in thalamocortical neurons (Table 1) .
Simultaneous Gene Transfer in Cultured Mammalian Cells. We next examined whether these three receptor-envelope pairs could be used simultaneously to deliver three different genes into three different cell populations in a single culture. For this purpose, we infected a mixture of EnvA/EnvB/EnvE vectors, each expressing different fluorescent proteins, into an intermingled population of HEK 293T cells in which each cell expressed one of the three receptor proteins (TVA950, TVB S3 , or DR-46TVB) (Fig. 7A) . The infected cells expressed only one of the three fluorescent proteins in a mutually exclusive manner, creating a three-color cellular mosaic (Fig. 7B ). This result confirmed that the infection specificity of the three receptor-envelope pairs is preserved, even in the presence of nonoptimal receptors and Env vectors in vitro.
ASLV Receptor-Envelope Pairs Enable Triple Pathway-Specific Gene
Transfer in Vivo. To demonstrate the selective and simultaneous labeling of three neuronal populations-each projecting to different target regions-we injected three types of receptorexpressing vectors into the different cortical areas in S1 and a mixture of Env vectors into the thalamus (Fig. 8 A and B) . The injection coordinates for each receptor-expressing vector were the same as those shown in Figs. 4-6. In a confocal tiling of a sagittal section, we distinguished three XFPs in different axons (Fig. 8C) . BFP-, EGFP-, and tdTomato-positive axons innervated areas near each injection site. In the thalamus, neurons positive for all three types of fluorescence were present. Although the three Env vectors were injected at the same coordinates, the three types of XFP-positive neurons exhibited different distributions in the thalamus (Fig. 8D) . Most of the BFP-positive neurons were medial to the EGFP-positive neurons in the thalamus, and the EGFP-positive neurons were more medial than the tdTomato-positive neurons. Furthermore, individual neurons distinctly expressed BFP, EGFP, or tdTomato in a mutually exclusive manner (Fig. 8 E and F) . In conclusion, we identified three ASLV receptor-envelope pairs that are orthogonal in mammalian cells and rat brains. These pairs could be used simultaneously in single cultures or individual rats to fluorescently label three distinct subgroups of neurons.
Discussion
By experimentally identifying and characterizing ASLV receptor-envelope pairs in mammalian cells, we engineered a novel multitargeted gene-transfer system and conducted a proof-ofconcept study demonstrating that this system can genetically dissect intermingled neural connections in rat brains. The high orthogonality of three artificial ASLV receptors and their corresponding ASLV envelopes was key to the success of this system and permitted the ASLV-pseudotyped lentiviral vectors to selectively transduce mammalian cells expressing specific receptors in vitro and in vivo.
We combined FuGB2-pseudotyped lentiviral vector (35) with our receptor-envelope system to identify neural populations projecting to a target region in the brain. This retrograde genetransfer method was selected based on its high efficiency of retrograde transduction via axon terminals (24, 35) . Various types of pseudotyped lentiviral vectors, including FuGB2 vector, were developed to achieve retrograde gene transfer by fusing rabies virus glycoprotein to vesicular stomatitis virus glycoprotein (VSV-G) (25, (35) (36) (37) (38) . The FuGB-and FuGB2-pseudotyped lentiviral vectors show highly efficient retrograde gene transfer (HiRet series) (25, 35) . Furthermore, the FuGC-and FuGEpseudotyped lentiviral vectors show neuron-specific retrograde gene transfer (NeuRet series), but exhibit lower efficiency than that of the HiRet series (37, 38) . Therefore, although the NeuRet series was developed after the HiRet series, FuGB2-pseudotyped lentiviral vector is the system that yields the highest efficiency of retrograde gene transfer. Based on these reports, we selected the FuGB2 vector in this study. Although we believe the three ASLV receptor-envelope pairs would also work with the NeuRet series, in vivo tests are necessary to check the NeuRet efficiency for each experimental design. Importantly, to use NeuRet series instead of HiRet, it is necessary to optimize the titers and the waiting time between the injection of NeuRet and Env vectors beforehand. Our system can also be combined with other retrograde genetransfer methods, such as recombinant rabies virus (5, 27, 39-43) and adeno-associated virus (AAV) vectors (44) (45) (46) (47) . However, ASLV pseudotyping may change the pH tolerance and stability of viral particles (48-50); consequently, the infectious titer of viral vectors should be checked before use. Reports about retrograde transduction by AAV vector appear inconsistent; it has been reported as weak or ineffective in some cases (51, 52) and effective in others (44, 45) . In addition to this inconsistency, AAV serotypes 8 and 9, which are known to undergo retrograde axonal transport, also anterogradely transduce second-order neurons in vivo (53) . This anterograde transport of AAV vector is not suitable for pathway-specific gene expression. Related, the HiRet or NeuRet series selectively undergo retrograde, but not anterograde, axonal transport (24, 25, (36) (37) (38) .
ASLVs are divided into six viral subgroups, designated A-E and J, based on their cellular receptors (11) . From these ASLV subgroups and receptors, we screened for specificity and efficiency using HEK 293T cells and rat brains. In our in vitro assays, the infection rate of the TVB T -EnvB pair was lower than that of TVB T -EnvE pair, but much higher than that of control (Fig. 3) . However, TVB T is reported to permit entry of retroviral vector pseudotyped with EnvE, but not EnvB (15). Because we used EnvB-pseudotyped lentiviral vectors at high MOI (MOI = 100), weak receptor-envelope interaction was perhaps detected in our experimental condition. With the TVC-EnvC pair, EnvC vector transduced TVC-expressing neurons only in the absence of other Env vectors (Fig. S3) ; the reason for these conflicting results remains unclear. Some viruses, such as HIV and hepatitis C virus, use multiple cellsurface components to enter host cells (10) . Hence, we speculate that ASLV(C)-pseudotyped lentiviral vectors might require factors other than TVC that are occupied by the other Env vectors (EnvA, EnvB, and EnvE).
In our system, the main factor that determines the transduction efficiency is the expression level of the receptor that interacts with the Env vectors. To increase the efficiency, a 2-to 3-wk period between the injection of FuGB2 and Env vectors is necessary to achieve sufficient expression of the receptors. To increase receptor expression, two refinements are necessary: codon optimization for mammals and shortening of the receptor sequence. Both refinements are expected to increase protein expression level.
To apply our system into optogenetic tools, the insert length will become a problem. The RNA titer of lentiviral vectors decreases with increasing insert length (54) . In addition, the ability of ASLV envelope to pseudotype lentiviral vectors is poor relative to that of VSV-G envelope glycoprotein, as demonstrated by its relatively low physical and infectious titers (49) . However, we produced Env vectors containing tdTomato (1,475 bp) at high titers [EnvB-tdTomato 8.8 × 10 10 transduction units (TU)/mL; EnvE-tdTomato 6.15 × 10 10 TU/mL), and they worked well in in vivo experiments (Figs. 6 and 8) . Possible candidates of frequently used optogenetic tools include hChR2-EYFP (1,662 bp), eNpHR3.0-EYFP (1,683 bp), ChETA-EYFP (1,662 bp), GCaMP6f (1,353 bp), and ArchT-GFP (1,475 bp) (55) (56) (57) (58) (59) . In GCaMP6f and ArchT-GFP, because the lengths of their DNA sequences are similar to tdTomato, we could produce Env vectors expressing these tools at sufficiently high titers to be used in practice. In hChR2-, eNpHR3.0-, and ChETA-EYFP, because their DNA sequences are not so much longer than that of tdTomato, the titer of Env vectors expressing them could not decrease so much. We will proceed to the next step to apply our receptor-envelope pairs to the frequently used optogenetic tools.
One advantage of this receptor-envelope system is its compatibility with other gene-expression systems. Combining the Cre/loxP and Tet system (6, 60) with the receptor-envelope system allows modifiers of neural activity-such as channelrhodopsin-2 (61, 62), tetanus toxin (63-65), allatostatin (66) , and immunotoxin (67-69)-to be selectively introduced and expressed in a more limited population of cell types. In addition, the combination of new optogenetic tools activated by different light wavelengths (70, 71) with the receptor-envelope system may allow the manipulation of each connection separately and simultaneously. Therefore, when combined with other emerging technologies, the system we describe here should make a powerful contribution to the functional analysis of multiple neural populations in vivo.
Materials and Methods
All experiments were approved by the Institutional Review Committee of the University of Tokyo School of Medicine. Lentiviral vectors were produced by cotransfection of HEK293T cells with four plasmids (Table S3 ) and titrated as described (25, 26) . In in vitro experiments, HEK293T cells were serially infected by the FuGB2 vector and the Env vector (3 d after FuGB2 vector infection). Three days later, infected HEK293T cells were collected and fixed with 4% (wt/vol) paraformaldehyde, and analyzed by using fluorescence microscopy or flow cytometer. In in vivo experiments, ten-week-old rats were serially injected with the FuGB2 vector (somatosensory cortex) and the Env vectors (thalamus, 3 wk after FuGB2 vector injections). Injected rats were then perfused with 4% (wt/vol) paraformaldehyde and their brains were processed for histological analyses as described (26) . All data are presented as mean ± SE (SEM). We considered P < 0.01 as significant statistical differences. Additional materials and methods, including procedures for in vitro experiments, are provided in SI Materials and Methods. The sequences for naive and synthetic  receptors (TVA950, TVB S3 , TVC, TVB T , and DR-46TVB) for ASLV subgroups were as follows. TVA950. TVA, consisting of the long-form splice variant TVA950 from chicken line H6, and the HA epitope tag was obtained from plasmid pTVA950(H6) (2). This sequence was subcloned into the lentiviral transfer vector containing the CMV promoter (3) and then subcloned into a bicistronic lentiviral transfer vector that coexpressed a GFP (AcGFP1) and a receptor protein mediated by the picornaviral 2A peptide (P2A) under the control of the CMV promoter (4). TVB S3 . TVB S3 consisted of TVB S3 ΔDD (amino acids 1-280) and a c-Myc epitope tag. TVB proteins contain a putative cytoplasmic death domain (DD), which promotes cell death after envelope-receptor interaction (5, 6) . TVB S1 , a chicken receptor for the ASLV subgroups B, D, and E, differs from TVB S3 exclusively at residue 62 (7). The TVB S1 fragment was obtained from the pHA1 plasmid (5), and cysteine 62 was converted to serine, which converted the TVB S1 fragment into the TVB S3 fragment (7). The c-Myc epitope tag was fused to the C terminus, and the resulting fragment was subcloned into the lentiviral transfer vector and the bicistronic lentiviral transfer vector. TVC. TVC consisted of the chicken line H6 TVC protein (amino acids 1-488) and a V5 epitope tag. TVC sequence was obtained from plasmid pTVC-F (8). The V5 epitope tag was fused to the C terminus, and the resulting fragment was subcloned into the lentiviral transfer vector and the bicistronic lentiviral transfer vector. TVB T . TVB T consisted of TVB T ΔDD (amino acids 1-281) and a Flag epitope tag. TVB T sequence was obtained from plasmid TEF24ΔDD (9) . The FLAG epitope tag was fused to the C terminus, and the resulting fragment was subcloned into the lentiviral transfer vector and the bicistronic lentiviral transfer vector. DR-46TVB. DR-46TVB consisted of DR5 (amino acids 1-80), TVB S1 (amino acids 46-280), and a FLAG epitope tag (10) . The DR5 sequences were isolated from the HEK 293T cDNA library by PCR. TVB S1 (amino acids 1-45) was exchanged for DR5 (amino acids 1-80), and the FLAG epitope tag was fused to the C terminus. The fragment was subcloned into the lentiviral transfer vector and the bicistronic lentiviral transfer vector.
In this study, lentiviral vectors expressing fluorescent proteins were pseudotyped by using the ASLV envelopes EnvA/VSVG, EnvB, EnvC, and EnvE, respectively. Fragments of fluorescent proteins were subcloned into lentiviral transfer vectors containing the CMV promoter. The BFP fragment was obtained from pTagBFP-N (Evrogen), the AcGFP1 fragment was from pIRES2-AcGFP1, the mCherry fragment was from pmCherry-N1, and the tdTomato fragment was from pCMV-tdTomato (all from Clontech Laboratories).
Cell Culture. HEK 293T cells were obtained from the RIKEN BioResource Center (Tsukuba; cell no. RCB2202). HEK 293T cells were maintained in DMEM (Life Technologies) supplemented with 10% (vol/vol) FBS, 100 U/mL penicillin G, and 100 μg/mL streptomycin (Life Technologies). Cells were cultured at 37°C in a 5% CO 2 atmosphere.
Viral Vector Production and Titration. HEK 293T cells were plated in 4-× 150-mm dishes, and the next day, the cells were transfected with 100 μg of transfer plasmid, 20 μg of envelope plasmid, 20 μg of pCAG4-RTR2, and 20 μg of pCAG-kGP1.1R by using the calcium phosphate method. The detailed procedure for virus production has been described (4). All plasmids used in this study are listed in Table S3 . The titers of FuGB2 vectors were determined by the DNA titration method as described (11) . Briefly, cultured HEK 293T cells were transduced, their genomic DNA was extracted, and the copy number of integrated lentiviral genomes was analyzed by performing TaqMan real-time PCR for the Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) sequence (11) . Titers of the Env vectors were determined by the RNA titration method (12) using the Lenti-X quantitative RT-PCR Titration Kit (Clontech Laboratories). After plating, HEK 293T cells were fixed with 4% (wt/vol) paraformaldehyde (PFA) in PBS at room temperature for 15 min. After washing with PBS, four-well plates were coverslipped by using Fluoroshield Mounting Medium (ImmunoBioScience) and examined by using a Zeiss LSM 780 confocal microscope (Carl Zeiss Microscopy). For flow cytometry, 3 d after infection with the Env vector, HEK 293T cells were harvested and fixed with 2% (wt/vol) PFA in PBS at 4°C for 15 min. Cells were resuspended in 1.0 mL of PBS and then filtered through a 40-μm nylon membrane (Kyoshin Rikoh). Samples of 10,000 cells were analyzed, and the fraction of AcGFP1-or mCherry-positive cells was determined by using an EPICS XL flow cytometer equipped with the EXPO 32 software (Beckman Coulter) and FlowJo software (Tree Star) (3).
Surgical Procedures and Viral Injections into Rat Cortices and
Thalamus. Ten-week-old male Wistar rats (Nihon SLC) were housed in groups (three or four animals per cage) and had free access to rat pellet chow and water. Each rat was anesthetized with a mixture of ketamine and xylazine (90 and 10 mg/kg, respectively) injected intraperitoneally. Rats were positioned in a stereotactic frame (SR-6R; Narishige), and body temperature was maintained at 37°C by using a rectal probe and a heating pad (BWT-100A; BRC). An incision was made in the scalp, and a small craniotomy was made to target the injection area. The dura was punctured, and the virus was delivered via a 32-gauge needle attached to a 10-μL gas-tight Hamilton syringe (Hamilton Co.). After the injection, the scalp was sutured.
Viral vectors were injected into the rats twice in the experiments in Figs. 4-6 and 8. First, one or all three receptorexpressing vectors were injected into the somatosensory cortices; second, a mixture of EnvA/B/E vectors was injected into the thalamus. In the first injection, 1.5 μL of FuGB2 vector (titer: 4.0 × 10 10 TU/mL) was injected to a depth of 600 μm below the dura surface at the rate of 100 nL/min for 15 min. The injection sites were as follows: FuGB2-TVA950 vector, anterior +1.5 mm from bregma and lateral 3.9 mm from the midline; FuGB2-TVB S3 vector, anterior −0.5 mm and lateral 3.9 mm; and FuGB2-DR-46TVB vector, anterior −2.5 mm and lateral 3.9 mm. The second injection was conducted 3 wk after the first injection. Env vectors (4.0 μL; a mixture of Env vectors, each adjusted to 2.0 × 10 10 TU/mL) were injected into the thalamus (anterior = −3.0 mm, lateral = 2.5 mm, and depth = 5.5 mm) for 40 min.
In the experiment in Fig. S2 , FuGB2-AcGFP1-P2A-TVC (1.5 μL; titer: 1.5 × 10 9 TU/mL) was injected into the somatosensory cortex (anterior = −2.5 mm, lateral = 3.9 mm, and depth = 600 μm) at the rate of 100 nL/min for 15 min; second, EnvC vector (4.0 μL; titer: 4.0 × 10 10 TU/mL) was injected into the thalamus (anterior = −3.0 mm, lateral = 2.5 mm, and depth = 5.5 mm) at the rate of 100 nL/min for 40 min 2 wk after the first injection.
In the experiment in Fig. S3 , FuGB2-AcGFP1 (1.5 μL; titer: 2.0 × 10 9 TU/mL) was injected into the somatosensory cortex (anterior = −2.5 mm, lateral = 3.9 mm, and depth = 600 μm) at the rate of 100 nL/min for 15 min.
In the experiment in Fig. S4 , one of the receptor-expressing FuGB2 vectors was injected into the right motor cortex; second, a mixture of EnvA/B/E vectors was injected into two sites in the left motor cortex. In the first injection, 1.5 μL of FuGB2 vector (titer: 1.0 × 10 10 TU/mL) was injected to the right motor cortex (anterior = +1.0 mm, lateral = 2.2 mm, and depth = 1000 μm) at the rate of 100 nL/min for 15 min. The second injection was conducted 2 wk after the first injection. Env vectors (1.5 μL; a mixture of Env vectors, each adjusted to 5.0 × 10 9 TU/mL) were injected into two sites in the left motor cortex (anterior = +0.5 mm, lateral = 2.2 mm, and depth = 1.0 mm; anterior = +1.5 mm, lateral = 2.2 mm, and depth = 1.0 mm) at the rate of 100 nL/min for 40 min.
Immunohistochemistry. Histology was performed as described (3) . Three weeks after Env vector injection, rats were transcardially perfused with saline and 4% (wt/vol) PFA in PBS. The brains were then postfixed in 4% PFA in PBS for 6 h, processed in 20% (wt/vol) sucrose in PBS, and embedded in optimum cutting temperature compound (Sakura). Brains were frozen with dry ice and cut into 25-μm-thick sections by using a cryostat (Leica CM 3050S). In the experiments in Figs. S2-S4, 2 wk after Env vector injection, rats were perfusion-fixed in the same manner as described above.
The immunohistochemistry was performed as described, with modifications (3). Brain sections were incubated in a blocking solution of 5% normal goat serum (NGS; Vector Laboratories) and 0.3% Triton X-100 in PBS for 30 min at room temperature and subsequently incubated with primary antibodies (with 5% NGS and 0.3% Triton X-100 in PBS) for 3 d at 4°C. On the last day, brain sections were incubated with secondary antibodies for 1 h at room temperature. After thorough washing, the sections were incubated with antibody against NeuN or the appropriate epitope tag (for cell counting) for 2 d at 4°C. The sections were incubated with biotin-conjugated goat anti-mouse antibody (1:500; Vector; BA-9200) in blocking solution for 30 min and then with Alexa Fluor 647 streptavidin (1:500; Molecular Probes; S-21374) for 1 h at room temperature. The sections in Fig. S3 were counterstained with Hoechst 33258 (Molecular Probes). Sections were coverslipped by using i-BRITE Plus (Neuromics) and stored at −20°C.
For BFP, EGFP, tdTomato, and NeuN staining, brain sections were visualized by using the following primary antibodies: chicken anti-GFP (1:1,000; Genetex; GTX13970), rabbit anti-tRFP (1:1,000; Evrogen; AB233), mouse anti-DsRed (1:1,000; Clontech; 632393), and mouse anti-NeuN (1:1,000; Millipore; MAB377). For cell count sections, fluorescence staining was also conducted by using the same primary antibodies as described above, and each epitope tag was visualized by using the following primary antibodies: mouse anti-HA (1:1,000; Covance; MMS-101R), mouse anti-c-Myc (1:1,000; MBL; M192-3S), or mouse anti-FLAG M2 (1:1,000; Sigma-Aldrich; F1804). The secondary antibodies used were goat anti-chicken Alexa Fluor 488 (1:500; Molecular Probes; A11039), goat anti-rabbit Alexa Fluor 405 (1:500; Molecular Probes; A31556), and goat anti-mouse Alexa Fluor 546 (1:500; Molecular Probes; A11035).
Image Collection and Cell Counting. Images of triple-colored cells and sections were captured by using a Zeiss LSM 780 confocal microscope and analyzed by using the ZEN Lite 2012 software (Carl Zeiss Microscopy). For cell counting, sections were imaged on a Keyence BZ-9000 Biorevo all-in-one fluorescence microscope by using the BZ-II analysis application. The same sections were also imaged on a Leica TCS SPE confocal microscope by using LAS AF Lite software (Leica). Quantitative in vivo data (Table 1 and Table S2 ) were obtained from sections stained to detect epitope tags. Five (Table 1) or three (Table S2) nonadjacent sections (every third section) were chosen in each rat. All fluorescence-positive and epitope-tag-positive neurons were manually counted from all fields of the sections. To determine the specificity of receptor-envelope pairs in vivo, the percentage of fluorescence-positive neurons that were also positive for the epitope tag (i.e., double-positive cells) was calculated.
Quantitative data about the number and distribution of FuGB2-infected neurons in Fig. S3 were obtained from five coronal brain sections separated by a distance of 1 mm in three rats (five sections in each rat, 1 mm apart, one of which included the injection site of the FuGB2 vector).
Statistical Analysis. For statistical analysis, the data were evaluated for significance by performing one-way ANOVA followed by Scheffé's F-test using Excel (Microsoft). Percentage values were arcsine-transformed before statistical analysis. P values < 0.01 were considered to represent statistically significant differences. Unless otherwise indicated, data are presented as means and SEM (13). The AcGFP1-positive neurons in the ipsilateral S1 at the injection site, ipsilateral S1 remote from the injection site, contralateral S1, ipsilateral S2, ipsilateral thalamus, and ipsilateral M1 are shown. The number of AcGFP1-positive neurons were counted in five coronal brain sections separated by a distance of 1 mm in each of three rats (five sections per rat, 1 mm apart, one of which included the injection site of the FuGB2 vector). Simple diffusion of the 1.5-μL virus solution extended to a region of <1 mm in diameter in the anterior-posterior and medial-lateral directions within the cortex (2) . Therefore, AcGFP1-positive neurons within 1-mm diameter centered on the injection site (59.0 ± 14.0 cells) were defined as local neurons possibly infected via soma or axon terminals and the others (851.3 ± 62.4 cells) as remote neurons infected via axon terminals. The frequency of somatic infection to axonal infection for the FuGB2 vector in the cortex was estimated as a ratio of the number of local neurons to remote neurons at most (0.070 ± 0.018). (Scale bar: 100 μm.) S2, secondary somatosensory cortex; ipsi, ipsilateral to the FuGB2 injection site; contra, contralateral to the FuGB2 injection site. Legend continued on following page stained with anti-HA antibody. The merged image of BFP (cyan) and TVA950-HA (purple) shows that BFP expression was observed in a subset of TVA950-HApositive neurons, whereas expression of EGFP (green) or tdTomato (red) was not observed. (Scale bar: 50 μm.) (E) Confocal images of a section stained with anti-c-Myc antibody. The merged image of EGFP (green) and TVB
S3
-c-Myc (purple) shows that EGFP expression was observed in a subset of TVB S3 -c-Mycpositive neurons, whereas expression of BFP (cyan) or tdTomato (red) was not observed. (Scale bar: 50 μm.) (G) Confocal images of a section stained with anti-3×-FLAG antibody. The merged image of tdTomato (red) and DR-46TVB-3×-FLAG (purple) shows that tdTomato expression was observed in a subset of DR-46TVB-3×-FLAG-positive neurons, whereas expression of BFP (cyan) or EGFP (green) was not observed. (Scale bar: 50 μm.) TVA950  A1  3  131  3  0  0  0  0  A2  3  101  2  0  0  0  0  A3  3  89  0  0  0  0  0  TVBS3+  TVBS3−  TVBS3+  TVBS3−  TVBS3+  TVBS3−  TVB   S3   B1  3  0  0  91  1  0  0  B2  3  0  0  77  2  0  0  B3  3  0  0  80  0  0  0  DR-46TVB+  DR-46TVB−  DR-46TVB+  DR-46TVB−  DR-46TVB+  DR-46TVB−  DR-46TVB  D1  3  0  0  0  0  94  1  D2  3  0  0  0  0  65  0  D3  3 FuGB2-AcGFP1-P2A-TVA950 pCAGGS-FuGB2 pCL20c-CMV-AcGFP1-P2A-TVA950-WPRE FuGB2-AcGFP1-P2A-TVB pCAGGS-FuGB2 pCL20c-CMV-DR-46TVB-WPRE EnvA-mCherry pCB6-WTA-VCT pCL20c-CMV-mCherry-WPRE EnvB-mCherry pAB7 pCL20c-CMV-mCherry-WPRE EnvC-mCherry pAB9 pCL20c-CMV-mCherry-WPRE EnvA-BFP pCB6-WTA-VCT pCL20c-CMV-BFP-WPRE EnvB-EGFP pAB7 pCL20c-CMV-EGFP-WPRE EnvC-tdTomato pAB9 pCL20c-CMV-tdTomato-WPRE Note: The packaging plasmids pCAG4-RTR2 and pCAG-kGP1.1R were used for all viral vector production.
